During Monday’s Current trade, Shares of Lululemon Athletica inc. (NASDAQ:LULU), gain 1.07% to $54.59.
lululemon athletica inc. (LULU) declared financial results for the second quarter ended August 2, 2015.
For the second quarter ended August 2, 2015:
- Net revenue for the quarter raised 16% to $453.0 million from $390.7 million in the second quarter of fiscal 2014.
- Total comparable sales, which comprises comparable store sales and direct to consumer, raised by 11% for the second quarter on a constant dollar basis.
- Comparable store sales for the second quarter raised by 6% on a constant dollar basis and direct to consumer revenue raised 35% on a constant dollar basis.
- Direct to consumer net revenue raised 30% to $82.2 million, or 18.2% of total Company revenue, in the second quarter of fiscal 2015, an enhance from 16.2% of total Company revenues in the second quarter of fiscal 2014.
lululemon athletica inc., together with its auxiliaries, designs, manufactures, and distributes athletic apparel and accessories for women, men, and female youth. It operates through two segments, Corporate-Owned Stores and Direct To Consumer. The company offers pants, shorts, tops, and jackets for healthy lifestyle activities and athletic pursuits, such as yoga, running, and general fitness; and dance-inspired apparel for female youth. It also provides fitness-related accessories, counting bags, socks, underwear, yoga mats, and water bottles.
Shares of Opko Health Inc. (NYSE:OPK), inclined 0.10% to $10.10, during its current trading session.
OPKO Health, Inc. (OPK) declared a global license agreement with The Scripps Research Institute (TSRI) for the development and commercialization of novel lipoprotein signal peptidase (“Lsp”) inhibitors developed and discovered using a proprietary high throughput screening technology funded and exclusively licensed by OPKO from TSRI.
OPKO has agreed to fund additional work in Dr. Wolan’s laboratory at TSRI and to move as rapidly as possible into clinical trials.
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics. The company develops various solutions to diagnose, treat, and prevent various conditions, counting point-of-care tests, molecular diagnostics tests, laboratory developed tests, and proprietary pharmaceuticals and vaccines. Its products comprise 4Kscore test that measures the blood plasma levels of four different prostate-derived kallikrein proteins.
Mylan NV (NASDAQ:MYL), during its Monday’s current trading session gained 0.29% to $48.79.
Perrigo Company plc (NYSE: PRGO; TASE) confirmed that Mylan N.V. (“Mylan”) (MYL) has commenced an unsolicited exchange offer to acquire all of the issued and to be issued ordinary shares of Perrigo. Shareholders are strongly advised to take no action in relation to the offer at this time pending the Board’s review.
The Board of Perrigo will assess Mylan’s offer and advise Perrigo shareholders of its recommendation regarding the exchange offer within 10 business days by making accessible to shareholders and filing with the U.S. Securities and Exchange Commission a solicitation/recommendation statement on Plan 14D-9 and in accordance with Rule 25 of the Irish Takeover Rules. Applicable securities laws restrict Perrigo’s ability to comment on Mylan’s offer until after its Plan 14D-9 has been filed.
Irish Takeover Rules
The directors of Perrigo accept responsibility for the information contained in this declarement. To the best of the knowledge and belief of the directors of Perrigo (who have taken all reasonable care to ensure such is the case), the information contained in this declarement is in accordance with the facts and does not omit anything likely to affect the import of such information.
A person interested in 1% or more of any class of relevant securities of Perrigo or Mylan may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2013 (“Irish Takeover Rules”).
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and the manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain administration, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form (FDF) products for the antiretroviral (ARV) market and non-ARV FDF products that are marketed to third parties.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
